Larimar Therapeutics (LRMR) EPS (Basic): 2012-2019
Historic EPS (Basic) for Larimar Therapeutics (LRMR) over the last 8 years, with Dec 2019 value amounting to -$1.22.
- Larimar Therapeutics' EPS (Basic) rose 71.43% to -$0.10 in Q1 2020 from the same period last year, while for Mar 2020 it was -$0.96, marking a year-over-year increase of 44.19%. This contributed to the annual value of -$1.22 for FY2019, which is 35.79% up from last year.
- Latest data reveals that Larimar Therapeutics reported EPS (Basic) of -$1.22 as of FY2019, which was up 35.79% from -$1.90 recorded in FY2018.
- Over the past 5 years, Larimar Therapeutics' EPS (Basic) peaked at -$1.22 during FY2019, and registered a low of -$2.78 during FY2015.
- Moreover, its 3-year median value for EPS (Basic) was -$1.90 (2018), whereas its average is -$1.67.
- Data for Larimar Therapeutics' EPS (Basic) shows a peak YoY spiked of 35.79% (in 2019) over the last 5 years.
- Larimar Therapeutics' EPS (Basic) (Yearly) stood at -$2.78 in 2015, then rose by 23.74% to -$2.12 in 2016, then rose by 10.38% to -$1.90 in 2017, then remained steady at -$1.90 in 2018, then surged by 35.79% to -$1.22 in 2019.